Tumor-associated immunoglobulin idiotype (Id) (Id)

The tumor-associated immunoglobulin idiotype (Id) represents the unique set of antigenic determinants located within the variable regions of the monoclonal immunoglobulin (B-cell receptor) expressed by malignant B cells. Because each B-cell malignancy, such as follicular lymphoma or multiple myeloma, originates from a single transformed B cell, the resulting tumor population displays a uniform and highly specific idiotype that is absent from normal B cells (Kwak et al., 1992). This makes the idiotype an ideal tumor-specific antigen for targeted immunotherapy. Therapeutic strategies include the administration of personalized idiotype vaccines, such as Id-KLH conjugates, which aim to stimulate the patient's own immune system to recognize and destroy the malignant clone (Schuster et al., 2011). Additionally, passive immunotherapy using monoclonal anti-idiotypic antibodies can directly target the receptor to induce apoptosis or immune-mediated cell death (Levy et al., 1982). Despite its high specificity, challenges remain, including the potential for tumor escape through the emergence of idiotype-negative variants and the logistical complexity of manufacturing patient-specific treatments (López-Requena et al., 2012).

Other names

B-cell receptor idiotypeClonal idiotypeTumor-specific idiotypeImmunoglobulin idiotype

Induction of active humoral and cellular immune responses against the unique clonal idiotype of the malignant B-cell receptor, leading to targeted destruction of tumor cells via antibody-dependent cellular cytotoxicity (ADCC), complement activation, or T-cell mediated cytotoxicity (López-Requena et al., 2012; Schuster et al., 2011).